Provides expertise and solutions in the main areas of materials (incl. nanofiltration membranes and CNT based composites), catalysis (incl. nanostructured metallomacrocycle carbons) and catalytic systems, electrochemistry, membranes and sensors focused in the energy, petrochemicals, environmental monitoring and remediation, defense and the aerospace industries.
eMagin integrates high-resolution OLED microdisplays, magnifying optics, and systems technologies to create a virtual image that appears comparable to that of a computer monitor or a large-screen television.
Open access for industry to a suite of state-of-the-art fabrication and characterisation equipment at BioCity Nottingham, UK. Focussed around the needs of industry for short-term, applications oriented development and assessment of nanotechnology approaches to improving products and processes.
Serving as a contract research organization, Endotherm Life Science Molecules is a provider of medicinally relevant compounds for the discovery and development of novel small molecule drugs. The product range includes focused compound libraries, building blocks and reagents for the development of biochemical assays (fluorescent and bioluminescent dyes).
EnerG2 Inc. is an advanced materials company addressing the commercial and technical challenges of energy storage. The company, in collaboration with the University of Washington Department of Materials Science & Engineering, has developed unique and proprietary sol-gel processing technologies in which colloidal suspensions are gelled to form a solid.
Energetiq is a developer and manufacturer of short wavelength light sources for use in advanced scientific and engineering applications. Its light sources are based on new technology that generates high brightness light in the 1nm to 250nm range with high reliability in a compact package.
Ensemble Therapeutics is utilizing DNA Programmed Chemistry (DPC), an innovative method for creating new chemical bonds. Ensemble integrates DPC into a nanoscale selection system that combines chemistry, biology and informatics to discover novel compounds.
The company is focused on the use of fullerene carbon nanotubes for novel therapeutic applications specifically in the area of cancer treatment. The company's extensive carbon nanotube-related, worldwide intellectual property portfolio includes discoveries by the late Nobel Prize winner Dr Rick Smalley. The use of fullerene carbon nanotubes has the goal of solving two important problems for many cancer therapeutics, that of delivering large active agents into the desired location and of protecting normal tissue from the active agent during delivery.